SUPN Form 144 shows 59,900-share sale after option exercise
Rhea-AI Filing Summary
Supernus Pharmaceuticals (SUPN) notice reports a proposed sale of 59,900 common shares, with an aggregate market value of $2,875,200, to be sold on or about
Positive
- Securities acquired by exercise of options and paid in cash, indicating no contingent consideration
- Sales executed under 10b5-1 plans, which are pre‑arranged and reduce timing uncertainty about insider intent
Negative
- Substantial recent insider sales across Aug–Oct 2025 with large gross proceeds (multiple trades above
$1M ) - Proposed sale on 10/09/2025 adds incremental supply equal to 59,900 shares (~0.11% of outstanding), potentially pressuring short-term liquidity
Insights
TL;DR: A near-term insider sale of 59,900 shares follows option exercise and ongoing 10b5-1 sales.
The transaction shows the filer exercised options
This pattern indicates planned liquidity events rather than ad-hoc disposals; monitor near-term total insider sell volume relative to the company’s outstanding shares (56,073,088) over the next few weeks for potential market supply effects.
TL;DR: The sale size is modest relative to shares outstanding but could add short-term supply pressure on trading days around
The proposed sale equals roughly 0.11% of the disclosed 56,073,088 shares outstanding, which is small in isolation. However, cumulative 10b5-1 sales listed (multiple trades across months) represent larger absolute proceeds and could affect intraday liquidity on sales dates.
Watch trading volume on